The ditans, a new class for acute migraine: Minireview
Lasmiditan (LDT), a new drug, was approved by the Food and Drug Administration in October 2019 for acute migraines with or without aura. LDT belongs to a new class of drugs “-ditans,” in which the mechanism is different from the triptans since it does not show vasoactive effects. The “-ditans” are m...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
| Series: | Journal of Current Research in Scientific Medicine |
| Subjects: | |
| Online Access: | http://www.jcrsmed.org/article.asp?issn=2455-3069;year=2020;volume=6;issue=1;spage=11;epage=14;aulast=Rissardo |